MARKET

MRSN

MRSN

Mersana
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.64
-0.31
-4.46%
Closed 16:00 11/29 EST
OPEN
7.15
PREV CLOSE
6.95
HIGH
7.15
LOW
6.64
VOLUME
759.92K
TURNOVER
--
52 WEEK HIGH
29.09
52 WEEK LOW
6.64
MARKET CAP
477.49M
P/E (TTM)
-3.0967
1D
5D
1M
3M
1Y
5Y
Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high ...
GlobeNewswire · 6d ago
BRIEF-Mersana Therapeutics And Synaffix B.V. Enter Into An Amended, Restated Commercial License And Option Agreement
reuters.com · 6d ago
Mersana Therapeutics's Return On Capital Employed Insights
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in a loss of $45.39 million.
Benzinga · 11/10 16:51
Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high ...
GlobeNewswire · 11/10 13:00
--Baird Adjusts Price Target on Mersana Therapeutics to $23 From $30, Keeps Outperform Rating
MT Newswires · 11/10 12:46
--Wedbush Trims Price Target for Mersana Therapeutics to $23 From $25, Maintains Outperform Rating
MT Newswires · 11/09 14:52
BRIEF-Mersana Therapeutics Files For Mixed Shelf Of Up To $300 Million
reuters.com · 11/09 14:33
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 11/09 12:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRSN. Analyze the recent business situations of Mersana through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
28.57%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRSN stock price target is 22.67 with a high estimate of 28.00 and a low estimate of 11.00.
High28.00
Average22.67
Low11.00
Current 6.64
EPS
Actual
Estimate
-0.54-0.40-0.27-0.13
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 157
Institutional Holdings: 78.77M
% Owned: 109.54%
Shares Outstanding: 71.91M
TypeInstitutionsShares
Increased
44
5.43M
New
12
2.73M
Decreased
33
3.85M
Sold Out
32
4.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.73%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Anna Protopapas
Senior Vice President - Finance
Brian Deschuytner
Senior Vice President
Mohan Bala
Senior Vice President
Alejandra Carvajal
Senior Vice President
Tushar Misra
Chief Technology Officer
Timothy Lowinger
Other
Arvin Yang
Independent Director
Lawrence Alleva
Independent Director
Willard Dere
Independent Director
Allene Diaz
Independent Director
Andrew Hack
Independent Director
Kristen Hege
Independent Director
Martin Huber
No Data
About MRSN
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.

Webull offers kinds of Mersana Therapeutics Inc stock information, including NASDAQ:MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRSN stock methods without spending real money on the virtual paper trading platform.